T-Regulatory Link of the Immune System and Its Role in the Pathogenesis of Inflammation and Carcinogenesis of the Lungs-Scilight

Trends in Immunotherapy

Review

T-Regulatory Link of the Immune System and Its Role in the Pathogenesis of Inflammation and Carcinogenesis of the Lungs

Downloads

https://doi.org/10.54963/ti.v9i3.1199
kobylyansky, V. I. (2025). T-Regulatory Link of the Immune System and Its Role in the Pathogenesis of Inflammation and Carcinogenesis of the Lungs. Trends in Immunotherapy, 9(3), 151–163. https://doi.org/10.54963/ti.v9i3.1199
Volume 9 Issue 3 (September 2025) (in progress)
Copyright (c) 2025 Vyacheslav Ivanovich kobylyansky
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Vyacheslav Ivanovich kobylyansky

    Research Institute of Pulmonology of the Federal Medical and Biological Agency of Russia, 115682, Orekhovy Bulvar 28, Moscow, Russian Federation

Received: 26 April 2025; Revised: 9 May 2025; Accepted: 23 June 2025; Published: 18 August 2025

The lack of awareness among the general medical audience about the central link in the lung immune system―T-regulatory cells (Treg) and the existing contradictions on this issue necessitate consideration and analysis, which is the purpose of this work. An analysis of 63 full-text literary sources, selected from the primary information databases, was conducted. An assessment of Treg in maintaining immune status is provided, indicating that they play a central role in balancing proinflammatory and anti-inflammatory cytokines, thereby maintaining the body's homeostasis. Their primary function is reflected in the generally accepted paradigm underlying the diagnosis and treatment of immune system disorders, which consists of an immunosuppressive effect with complex, ambivalent manifestations. This effect limits inflammatory reactions, especially hyperergic ones, but simultaneously contributes to the suppression of the antitumor immune response and stimulation of carcinogenesis processes. A decrease in Tregs is associated with opposite effects that depend on the nature of the relationship between the tumor and inflammation, and requires immunoprecise therapeutic effects. By influencing Tregs, it is possible to target and effectively modulate the processes of inflammation and carcinogenesis in the lungs. The depletion of the T-regulatory cell population is directly proportional to antitumor activity and inflammation intensity, and inversely proportional to tumor progression and inflammation regression. The opinion of some researchers that depletion of Treg cells reduces inflammation is unfounded and contradicts the generally accepted paradigm.

Keywords:

T‑Regulatory Cells Interleukin‑2 Inflammation Carcinogenesis

References

  1. Contreras-Castillo, E.; García-Rasilla, V.Y.; García-Patiño, M.G.; et al. Stability and Plasticity of Regulatory T Cells in Health and Disease. J. Leukoc. Biol. 2024, qiae049.
  2. Okeke, E.B.; Uzonna, J.E. The Pivotal Role of Regulatory T Cells in the Regulation of Innate Immune Cells. Front. Immunol. 2019, 10, 680.
  3. Charbonnier, L.M.; Chatila, T.A. Phenotypic and Functional Characterization of Regulatory T Cell Populations. In Signaling Mechanisms Regulating T Cell Diversity and Function, 1st ed.; Soboloff, J., Kappes, D.J., Eds.; CRC Press/Taylor & Francis: Boca Raton, FL, USA, 2018; Chapter 7.
  4. Mock, J.R.; Garibaldi, B.T.; Aggarwal, N.R.; et al. Foxp3+ Regulatory T Cells Promote Lung Epithelial Proliferation. Mucosal Immunol. 2014, 7, 1440–1451.
  5. Sakaguchi, S.; Sakaguchi, N.; Asano, M.; et al. Immunologic self-Tolerance Maintained by Activated T Cells Expressing IL-2 Receptor Alpha-Chains (CD25). Breakdown of a Single Mechanism of Self-Tolerance Causes Various Autoimmune Diseases. J. Immunol. 1995, 155, 1151–1164.
  6. Sagoo, P.; Ali, N.; Garg, G.; et al. Human Regulatory T Cells With Alloantigen Specificity are More Potent Inhibitors of Alloimmune Skin Graft Damage Than Polyclonal Regulatory T Cells. Sci. Transl. Med. 2011, 3, 83ra42.
  7. Xiao, F.; Ma, L.; Zhao, M.; et al. Ex Vivo Expanded Human Regulatory T Cells Delay Islet Allograft Rejection via Inhibiting Islet-Derived Monocyte Chemoattractant Protein-1 Production in CD34+ Stem Cells-Reconstituted NOD-scid IL2rγnull Mice. PLoS ONE 2014, 9, e90387.
  8. Dominguez-Villar, M.; Hafler, D.A. Regulatory T Cells in Autoimmune Disease. Nat. Immunol. 2018, 19(7), 665–673.
  9. Trzonkowski, P.; Bieniaszewska, M.; Juścinska, J.; et al. First-in-Man Clinical Results of the Treatment of Patients With Graft Versus Host Disease With Human Ex Vivo Expanded CD4+CD25+CD127− T Regulatory Cells. Clin. Immunol. 2009, 133, 22–26.
  10. Romano, M.; Fanelli, G.; Albany, C.J.; et al. Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity. Front. Immunol. 2019, 10, 43.
  11. Khan, M.A. Regulatory T Cells Mediated Immunomodulation During Asthma: a Therapeutic Standpoint. J. Transl. Med. 2020, 18(1), 456.
  12. Gladstone, D.E.; D'Alessio, F.; Howard, C.; et al. Randomized, Double-Blinded, Placebo-Controlled Trial of Allogeneic Cord Blood T-Regulatory Cells for Treatment of COVID-19 ARDS. Blood Adv. 2023, 7(13), 3075–3079.
  13. Revilla, S.A.; Kranenburg, O.; Coffer, P.J. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting. Front. Immunol. 2022, 13, 903564.
  14. Zhang, A.; Fan, T.; Liu, Y.; et al. Regulatory T Cells in Immune Checkpoint Blockade Antitumor Therapy. Mol. Cancer 2024, 23, 251.
  15. Xie, Y.J.; Tian, S.; Huang, M.; et al. Depletion of Regulatory T Cells Enhancing the Anti-Tumor Effect of In Situ Vaccination in Solid Tumors. Pharmacol. Res. 2024, 203, 107174.
  16. Iglesias-Escudero, M.; Arias-González, N.; Martínez-Cáceres, E. Regulatory Cells and the Effect of Cancer Immunotherapy. Mol. Cancer 2023, 22, 26.
  17. Tanaka, A.; Sakaguchi, S. Targeting Treg Cells in Cancer Immunotherapy. Eur. J. Immunol. 2019, 49, 1140–1146.
  18. Qin, D.; Zhang, Y.; Shu, P.; et al. Targeting Tumor-Infiltrating Tregs for Improved Antitumor Responses. Front. Immunol. 2024, 15, 1.
  19. Nishikawa, H.; Koyama, S. Mechanisms of Regulatory T Cell Infiltration in Tumors: Implications for Innovative Immune Precision Therapies. J. Immunother. Cancer 2021, 9, e002591. Erratum in: J. Immunother. Cancer 2021, 9, e002591corr1.
  20. Whiteside, T.L. What Are Regulatory T Cells (Treg) Regulating in Cancer and Why? Semin. Cancer Biol. 2012, 22, 327–334.
  21. Akkız, H.; Şimşek, H.; Balcı, D.; et al. Inflammation and Cancer: Molecular Mechanisms and Clinical Consequences. Front. Oncol. 2025, 15, 1564572.
  22. Greten, F.R.; Grivennikov, S.I. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity 2019, 51, 27–41.
  23. Malfertheiner, P.; Camargo, M.C.; El-Omar, E.; et al. Helicobacter pylori Infection. Nat. Rev. Dis. Primers 2023, 9, 19.
  24. Zhang, D.; Liu, H.; Zhao, F.; et al. Exploring the Relationship Between Treg-Mediated Risk in COPD and Lung Cancer Through Mendelian Randomization Analysis and scRNA-seq Data Integration. BMC Cancer 2024, 24, 453.
  25. Qu, Y.L.; Liu, J.; Zhang, L.X.; et al. Asthma and the Risk of Lung Cancer: A Meta-Analysis. Oncotarget 2017, 8, 11614–11620. Erratum in: Oncotarget 2017, 8, 48525.
  26. Metwally, E.M.; Lund, J.L.; Drummond, M.B.; et al. COPD With Lung Cancer Among Older United States Adults: Prevalence, Diagnostic Timeliness, and Association With Earlier Stage Tumors. Chronic Obstr. Pulm. Dis. 2024, 11, 382–385.
  27. Young, R.P.; Hopkins, R. The Potential Impact of Chronic Obstructive Pulmonary Disease in Lung Cancer Screening: Implications for the Screening Clinic. Expert Rev. Respir. Med. 2019, 13, 699–707.
  28. Tsay, J.J.; Wu, B.G.; Sulaiman, I.; et al. Lower Airway Dysbiosis Affects Lung Cancer Progression. Cancer Discov. 2021, 11, 293–307.
  29. Cebula, A.; Seweryn, M.; Rempala, G.A.; et al. Thymus-Derived Regulatory T Cells Contribute to Tolerance to Commensal Microbiota. Nature 2013, 497, 258–262.
  30. Hadis, U.; Wahl, B.; Schulz, O.; et al. Intestinal Tolerance Requires Gut Homing and Expansion of FoxP3+ Regulatory T Cells in the Lamina Propria. Immunity 2011, 34, 237–246.
  31. Zheng, D.; Liwinski, T.; Elinav, E. Interaction Between Microbiota and Immunity in Health and Disease. Cell Res. 2020, 30, 492–506.
  32. Zhao, H.; Wu, L.; Yan, G.; et al. Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention. Signal Transduct. Target Ther. 2021, 6, 263.
  33. Mantovani, A.; Allavena, P.; Sica, A.; et al. Cancer-Related Inflammation. Nature 2008, 454, 436–444.
  34. Littwitz-Salomon, E.; Malyshkina, A.; Schimmer, S.; et al. The Cytotoxic Activity of Natural Killer Cells Is Suppressed by IL-10+ Regulatory T Cells During Acute Retroviral Infection. Front. Immunol. 2018, 9, 1947.
  35. Quillien, V.; Carpentier, A.F.; Gey, A.; et al. Absolute Numbers of Regulatory T Cells and Neutrophils in Corticosteroid-Free Patients Are Predictive for Response to Bevacizumab in Recurrent Glioblastoma Patients. Cancer Immunol. Immunother. 2019, 68, 871–882.
  36. Lin, S.; Wu, H.; Wang, C.; et al. Regulatory T Cells and Acute Lung Injury: Cytokines, Uncontrolled Inflammation, and Therapeutic Implications. Front. Immunol. 2018, 9, 1545.
  37. Arce-Sillas, A.; Álvarez-Luquín, D.D.; Tamaya-Domínguez, B.; et al. Regulatory T Cells: Molecular Actions on Effector Cells in Immune Regulation. J. Immunol. Res. 2016, 2016, 1720827.
  38. Xu, Z.; Jiang, X.; Dai, X.; et al. The Dynamic Role of FOXP3+ Tregs and Their Potential Therapeutic Applications During SARS-CoV-2 Infection. Front. Immunol. 2022, 13, 916411.
  39. Muyayalo, K.P.; Huang, D.H.; Zhao, S.J.; et al. COVID-19 and Treg/Th17 Imbalance: Potential Relationship to Pregnancy Outcomes. Am. J. Reprod. Immunol. 2020, 84, e13304.
  40. Kalfaoglu, B.; Almeida-Santos, J.; Tye, C.A.; et al. T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis. Front. Immunol. 2020, 11, 589380.
  41. Yang, J.; Zhang, E.; Zhong, M.; et al. Impaired T Cell Functions Along With Elevated Activated Tregs at the Early Stage of Asymptomatic SARS-CoV-2 Infection. medRxiv 2020.
  42. Dhawan, M.; Rabaan, A.A.; Alwarthan, S.; et al. Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities With a Special Focus on Long COVID. Vaccines (Basel) 2023, 11, 699.
  43. Wang, W.; Su, B.; Pang, L.; et al. High-Dimensional Immune Profiling by Mass Cytometry Revealed Immunosuppression and Dysfunction of Immunity in COVID-19 Patients. Cell. Mol. Immunol. 2020, 17, 650–652.
  44. Hoyer, K.K.; Dooms, H.; Barron, L.; et al. Interleukin-2 in the Development and Control of Inflammatory Disease. Immunol. Rev. 2008, 226, 19–28.
  45. Harris, F.; Berdugo, Y.A.; Tree, T. IL-2-Based Approaches to Treg Enhancement. Clin. Exp. Immunol. 2023, 211, 149–163.
  46. Fontenot, J.D.; Rasmussen, J.P.; Gavin, M.A.; et al. A Function for Interleukin 2 in Foxp3-Expressing Regulatory T Cells. Nat. Immunol. 2005, 6, 1142–1151. Erratum in: Nat. Immunol. 2006, 7, 427.
  47. Fan, M.Y.; Low, J.S.; Tanimine, N.; et al. Differential Roles of IL-2 Signaling in Developing Versus Mature Tregs. Cell Rep. 2018, 25, 1204–1213.
  48. Ye, C.; Brand, D.; Zheng, S.G. Targeting IL-2: An Unexpected Effect in Treating Immunological Diseases. Signal Transduct. Target Ther. 2018, 3, 2.
  49. Cheng, G.; Yu, A.; Malek, T.R. T-Cell Tolerance and the Multi-Functional Role of IL-2R Signaling in T-Regulatory Cells. Immunol. Rev. 2011, 241, 63–76.
  50. Takeshita, T.; Asao, H.; Ohtani, K.; et al. Cloning of the Gamma Chain of the Human IL-2 Receptor. Science 1992, 257, 379–382.
  51. Yu, A.; Snowhite, I.; Vendrame, F.; et al. Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. Diabetes 2015, 64, 2172–2183.
  52. Rosenzwajg, M.; Lorenzon, R.; Cacoub, P.; et al. Immunological and Clinical Effects of Low-Dose Interleukin-2 Across 11 Autoimmune Diseases in a Single, Open Clinical Trial. Ann. Rheum. Dis. 2019, 78, 209–217.
  53. Duan, R.; Huang, K.; Yu, T.; et al. Interleukin-2/Anti-Interleukin-2 Complex Attenuates Inflammation in a Mouse COPD Model by Expanding CD4+ CD25+ Foxp3+ Regulatory T Cells. Int. Immunopharmacol. 2024, 131, 111849.
  54. Goleij, P.; Rahimi, M.; Pourshahroudi, M.; et al. The Role of IL-2 Cytokine Family in Asthma. Cytokine 2024, 180, 156638.
  55. Jacobse, J.; Li, J.; Rings, E.H.H.M.; et al. Intestinal Regulatory T Cells as Specialized Tissue-Restricted Immune Cells in Intestinal Immune Homeostasis and Disease. Front. Immunol. 2021, 12, 716499.
  56. Goswami, T.K.; Singh, M.; Dhawan, M.; et al. Regulatory T Cells (Tregs) and Their Therapeutic Potential Against Autoimmune Disorders—Advances and Challenges. Hum. Vaccin. Immunother. 2022, 18, 2035117.
  57. Lu, Y.; Man, X.Y. Diversity and Function of Regulatory T Cells in Health and Autoimmune Diseases. J. Autoimmun. 2025, 151, 103357.
  58. Pukhalsky, A.L.; Shmarina, G.V. Stimulatory and Protective Effects of Alkylating Agents Applied in Ultra-Low Concentrations. Pharmacology 2001, 62, 129–132.
  59. Pukhal'skii, A.L.; Shmarina, G.V.; Aleshkin, V.A. Immune Dysfunction and Cognitive Deficit in Stress and Physiological Aging. Part II: New Approaches to Cognitive Disorder Prevention and Treatment [in Russian]. Vestn. Ross. Akad. Med. Nauk 2014, 30–37.
  60. Sinitsyn, E.A.; Zykova, A.A.; Shamin, R.V.; et al. Efficacy and Safety of Ultra-Low Dose Inhaled Melphalan in the Treatment of Hospitalized Patients With COVID-19 [in Russian]. Acta Biomed. Sci. 2022, 7, 12–23.
  61. Sokolov, E.I.; Zykov, K.A.; Pukhalsky, A.L.; et al. Inhalations of Ultra-Low Doses of Alkylating Drugs in the Treatment of Asthma [in Russian]. Pulmonologiya 2002, 82–88.
  62. Kobylyansky, V.I. Some Reflections on Immunosuppressants and Their Delivery to the Lungs by Aerosol in the Treatment of COVID-19 [in Russian]. Med. Immunol. 2023, 24, 1307–1318.
  63. Flores, C.; Fouquet, G.; Cruz Moura, I.; et al. Lessons to Learn from Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications. Front. Immunol. 2019, 10, 588.
  64. Traxinger, B.R.; Richert-Spuhler, L.E.; Lund, J.M. Mucosal Tissue Regulatory T Cells Are Integral in Balancing Immunity and Tolerance at Portals of Antigen Entry. Mucosal Immunol. 2022, 15, 398–407.
  65. Kobilyansky, V.I.; Artyushkin, A.V. USSR Author's Certificate for Invention No. 1524904 [in Russian]. 1989. Aerosol Therapy Method.
  66. Usmani, O.S.; Roche, N.; Jenkins, M.; et al. Consistent Pulmonary Drug Delivery with Whole Lung Deposition Using the Aerosphere Inhaler: A Review of the Evidence. Int. J. Chron. Obstruct. Pulmon. Dis. 2021, 16, 113–124.
  67. Norton, D.L.; Ceppe, A.; Tune, M.K.; et al. Bronchoalveolar Tregs Are Associated with Duration of Mechanical Ventilation in Acute Respiratory Distress Syndrome. J. Transl. Med. 2020, 18(1), 427.
  68. Alexander, A.G.; Kay, A.B.; Barnes, N.C. Trial of Cyclosporin in Corticosteroid-Dependent Chronic Severe Asthma. Lancet 1992, 339, 324–328.
  69. Fukava, H.; Limura, A.; Hoshiko, K.; et al. A Cyclosporin A/Maltosyl-α-Cyclodextrin Complex for Inhalation Therapy of Asthma. Eur. Respir. J. 2003, 22, 213–219.
  70. Yuan, Y.; Che, X.; Zhao, M. Development of Cyclosporine A Microemulsion for Parenteral Delivery. J. Microencapsul. 2015, 32, 273–280.
  71. European Patent Application. Cyclosporine Formulations for Use in the Prevention or Treatment of Pulmonary Chronic Graft Rejection. 2015. EP 3069711A1.
  72. Bustamante-Marin, X.M.; Ostrowski, L.E. Cilia and Mucociliary Clearance. Cold Spring Harb. Perspect. Biol. 2017, 9, a028241.
  73. Trammer, B.; Amann, A.; Haltner-Ukomadu, E.; et al. Comparative Permeability and Diffusion Kinetics of Cyclosporine A Liposomes and Propylene Glycol Solution from Human Lung Tissue into Human Blood Ex Vivo. Eur. J. Pharm. Biopharm. 2008, 70, 758–764.
  74. Ahmad, J.; Akhter, S.; Rizwanullah, M.; et al. Nanotechnology-Based Inhalation Treatments for Lung Cancer: State of the Art. Nanotechnol. Sci. Appl. 2015, 8, 55–66.
  75. Chen, B.L.; Hora, M. Method for Pulmonary Delivery of Interleukin-2. U.S. Patent Application Publication 2003, No. US 2003/0198602 A1.
  76. Zheltova, O.I.; Starostina, N.M.; Tikhonova, M.A.; et al. Efficacy of Ronoleukine in Treatment of Chronic Recurrent Infection [in Russian]. Med. Immunol. 2011, 13(2–3), 227–236.
  77. Egorova, V.N.; Babachenko, I.V.; Degtyareva, M.V.; et al. Interleukin-2: Clinical Use in Pediatric Practice [in Russian]. Publishing House “New Alternative Polygraphy”: Saint Petersburg, Russia, 2008.
  78. Huland, E.; Heinzer, H.; Huland, H.; et al. Overview of Interleukin-2 Inhalation Therapy. Cancer J. Sci. Am. 2000, 6, S104–S112.
  79. Ostroukhova, M.; Seguin-Devaux, C.; Oriss, T.B.; et al. Tolerance Induced by Inhaled Antigen Involves CD4(+) T Cells Expressing Membrane-Bound TGF-Beta and FOXP3. J. Clin. Invest. 2004, 114, 28–38.
  80. Strickland, D.H.; Stumbles, P.A.; Zosky, G.R.; et al. Reversal of Airway Hyperresponsiveness by Induction of Airway Mucosal CD4+CD25+ Regulatory T Cells. J. Exp. Med. 2006, 203, 2649–2660.
  81. Xu, W.; Lan, Q.; Chen, M.; et al. Adoptive Transfer of Induced-Treg Cells Effectively Attenuates Murine Airway Allergic Inflammation. PLoS One 2012, 7, e40314.